{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:21:14Z","timestamp":1777594874651,"version":"3.51.4"},"reference-count":21,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Daiichi Sankyo, Inc."},{"name":"inScience Communications, Springer Healthcare Ltd."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Non-recommended dosing occurs in ~25\u201350% of non-vitamin K antagonist oral anticoagulant prescriptions, with limited data for edoxaban. We analyzed edoxaban dosing patterns in atrial fibrillation patients from the Global ETNA-AF program, relating patterns to baseline characteristics and 1-year clinical outcomes. The following dosing groups were compared: non-recommended 60 mg (\u201coverdosed\u201d) vs. recommended 30 mg; non-recommended 30 mg (\u201cunderdosed\u201d) vs. recommended 60 mg. Most (22,166\/26,823; 82.6%) patients received recommended doses. Non-recommended dosing was more frequent near label-specified dose-reduction thresholds. Ischemic stroke (IS; HR 0.85, 95% CI 0.50\u20131.47; p = 0.6) and major bleeding (MB; HR 1.47, 95% CI 0.97\u20132.71; p = 0.07) did not differ between recommended 60 mg and \u201cunderdosed\u201d groups, whereas all-cause (HR 1.61, 95% CI 1.23\u20132.08; p = 0.0003) and cardiovascular deaths (HR 1.61, 95% CI 1.11\u20132.38; p = 0.01) were higher in the \u201cunderdosed\u201d group. Compared with recommended 30 mg, the \u201coverdosed\u201d group had lower IS (HR 0.51, 95% CI 0.28\u20130.98; p = 0.04) and all-cause death (HR 0.74, 95% CI 0.55\u20130.98; p = 0.03) without higher MB (HR 0.74, 95% CI 0.46\u20131.22; p = 0.2). In conclusion: non-recommended dosing was infrequent, but more common near dose-reduction thresholds. \u201cUnderdosing\u201d was not associated with better clinical outcomes. The \u201coverdosed\u201d group had lower IS and all-cause death without higher MB.<\/jats:p>","DOI":"10.3390\/jcm12051870","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T02:04:11Z","timestamp":1677463451000},"page":"1870","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation: One-Year Data from the Global ETNA-AF Program"],"prefix":"10.3390","volume":"12","author":[{"given":"Tze-Fan","family":"Chao","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11220, Taiwan"},{"name":"Institute of Clinical Medicine, Cardiovascular Research Center, National Yang Ming Chiao Tung University, Taipei 11217, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Unverdorben","sequence":"additional","affiliation":[{"name":"Global Specialty Medical Affairs, Daiichi Sankyo, Inc., Basking Ridge, NJ 07920, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1881-0197","authenticated-orcid":false,"given":"Paulus","family":"Kirchhof","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Heart and Vascular Centre Hamburg, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany"},{"name":"German Center for Cardiovascular Research (DZHK), Partner Site Hamburg\/Kiel\/L\u00fcbeck, 20246 Hamburg, Germany"},{"name":"Institute of Cardiovascular Sciences, University of Birmingham, IBR 136, Wolfson Drive, Birmingham B15 2TT, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiro","family":"Koretsune","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, National Hospital Organization Osaka National Hospital, Osaka 540-0006, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The Cardiovascular Institute, Tokyo 106-0031, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Crozier","sequence":"additional","affiliation":[{"name":"Global Specialty Medical Affairs, Daiichi Sankyo, Inc., Basking Ridge, NJ 07920, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ladislav","family":"Pecen","sequence":"additional","affiliation":[{"name":"Institute of Computer Science, Academy of Sciences of the Czech Republic, 18207 Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathy","family":"Chen","sequence":"additional","affiliation":[{"name":"Global Specialty Medical Affairs, Daiichi Sankyo, Inc., Basking Ridge, NJ 07920, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda P.","family":"Borrow","sequence":"additional","affiliation":[{"name":"Global Specialty Medical Affairs, Daiichi Sankyo, Inc., Basking Ridge, NJ 07920, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1637-574X","authenticated-orcid":false,"given":"Raffaele","family":"De Caterina","sequence":"additional","affiliation":[{"name":"Pisa University Hospital, University of Pisa, 56126 Pisa, Italy"},{"name":"Fondazione VillaSerena per la Ricerca, 65013 Citt\u00e0 Sant\u2019Angelo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_2","unstructured":"(2023, February 24). Rivaroxaban\u2013Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xarelto-epar-product-information_en.pdf."},{"key":"ref_3","unstructured":"(2023, February 24). Dabigatran\u2013Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/pradaxa-epar-product-information_en.pdf."},{"key":"ref_4","unstructured":"(2023, February 24). Apixaban\u2013Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/eliquis-epar-product-information_en.pdf."},{"key":"ref_5","unstructured":"(2023, February 24). Edoxaban\u2013Summary of Product Charactersitics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/eliquis-epar-product-information_en.pdf."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/bcp.14127","article-title":"Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: A systematic review","volume":"86","author":"Santos","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e014177","DOI":"10.1161\/JAHA.119.014177","article-title":"Label adherence of direct oral anticoagulants dosing and clinical outcomes in patients with atrial fibrillation","volume":"9","author":"Yu","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.jacc.2016.09.966","article-title":"Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: The ORBIT-AF II Registry","volume":"68","author":"Steinberg","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3349\/ymj.2019.60.3.277","article-title":"Label adherence for non-vitamin K antagonist oral anticoagulants in a prospective cohort of Asian patients with atrial fibrillation","volume":"60","author":"Lee","year":"2019","journal-title":"Yonsei Med. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/ehjcvp\/pvy041","article-title":"Outcomes associated with non-recommended dosing of rivaroxaban: Results from the XANTUS study","volume":"5","author":"Amarenco","year":"2019","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1016\/j.hrthm.2020.07.022","article-title":"Off-label dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation","volume":"17","author":"Chan","year":"2020","journal-title":"Heart Rhythm."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/MAJ.0000000000000349","article-title":"Physician\u2019s fear of anticoagulant therapy in nonvalvular atrial fibrillation","volume":"348","author":"Sen","year":"2014","journal-title":"Am. J. Med. Sci."},{"key":"ref_13","unstructured":"(2023, February 24). Edoxaban-Full Prescribing Information (US), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206316lbl.pdf."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/clc.23279","article-title":"The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: Rationale and design","volume":"42","author":"Agnelli","year":"2019","journal-title":"Clin. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"De Caterina, R., Kim, Y.H., Koretsune, Y., Wang, C.C., Yamashita, T., Chen, C., Reimitz, P.E., Unverdorben, M., and Kirchhof, P. (2021). Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the {Global Noninterventional ETNA-AF Program. J. Clin. Med., 10.","DOI":"10.3390\/jcm10040573"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.jacc.2020.07.045","article-title":"Mortality in patients with atrial fibrillation receiving nonrecommended doses of direct oral anticoagulants","volume":"76","author":"Camm","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40119-020-00188-1","article-title":"Use, persistence, efficacy, and safety of apixaban in patients with non-valvular atrial fibrillation in unselected patients in Germany. Results of the prospective Apixaban in Atrial Fibrillation (APAF) Registry","volume":"9","author":"Zeymer","year":"2020","journal-title":"Cardiol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.jacc.2020.12.053","article-title":"Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation","volume":"77","author":"Steffel","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/j.jacc.2017.03.600","article-title":"Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction","volume":"69","author":"Yao","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/eurheartj\/ehv466","article-title":"XANTUS: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation","volume":"37","author":"Camm","year":"2016","journal-title":"Eur. Heart J."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/5\/1870\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:43:28Z","timestamp":1760121808000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/5\/1870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,27]]},"references-count":21,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["jcm12051870"],"URL":"https:\/\/doi.org\/10.3390\/jcm12051870","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,27]]}}}